The short version of PPARδ agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-07. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
=== Cancer biology === With technological advances, this assay is becoming very beneficial especially in the cancer biology realm. A study was performed to better understand the role that claudin-7, a family of tight junction proteins, plays in cell migration in a type of human lung cancer cells. Due to the slower migration rate of claudin-7 knockdown cells, it supports the idea that this protein is important in cell migration an cell's ability to metastasize. Cells undergo sheet migration due to a multitude of signals and mechanisms when trying to close a wound, which is believed to be similar to the underlying mechanisms involved in metastasis.
Cetacaine is a topical anesthetic that contains the active ingredients benzocaine (14%), butamben (2%), and tetracaine hydrochloride (2%). Cetacaine also contains small amounts of benzalkonium chloride at 0.5% and 0.005% of cetyl dimethyl ethyl ammonium bromide all in a bland water-soluble base. Although Cetacaine has been widely used in the medical and dental fields, it has yet to be officially approved by the FDA. Cetacaine is produced by the company Cetylite Industries, Inc. and they provide Cetacaine in three forms: liquid, gel, and spray.
From 2018 to 2023, Sen served as an Indiana University Distinguished Professor. At Indiana University, he directed the Indiana Center for Regenerative Medicine and Engineering (ICRME) and held the J. Stanley Battersby Chair as Distinguished Professor of Surgery. He also served as Associate Dean of Research and Associate Vice President of Research. In 2020, Sen was awarded the Bicentennial Medal by the Indiana University President's Office. In 2021, Sen was elected as a Lifetime Fellow of the National Academy of Inventors. He currently serves as Editor-in-Chief of Antioxidants & Redox Signaling and Advances in Wound Care. In March 2026, the American Diabetes Association announced Sen as winner of the 2026 Roger E Pecoraro award. Sen is widely recognized for co-inventing tissue nanotransfection, a technology enabling in vivo tissue reprogramming. His team also identified vasculogenic fibroblasts in humans. His research also spans electroceutical approaches to infection management and the role of tocotrienol forms of natural vitamin E. Sen served as the principal investigator for the NIH Diabetic Foot Consortium TEWL study. The study recommended revising the FDA definition of wound closure to include restoration of skin barrier function, as wounds with high transepidermal water loss (TEWL) were more likely to recur. Sen has an H-index of 125.
=== Raman spectroscopy === Raman spectroscopy is a spectroscopic technique that provides non-destructive analysis capable of identifying components within mixtures with chemical specificity without complex sample preparation. Raman spectroscopy relies on photon scattering following visible light radiation, where the shift in photon energies corresponds to information about the system's vibrational modes and their frequencies. Upon obtaining vibrational modenfrequencies, qualitative classifications about the system can be both made and reinforced. Raman spectroscopy works well in parallel with microfluidic devices for many qualitative biological applications. For some applications, Raman spectroscopy is preferred over other detection methods such as infrared (IR) spectroscopy as water has a strong interference signal with IR but not with Raman. Likewise, methods such as high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR), mass spectrometry (MS), or gas chromatography (GC) are also not ideal as these methods require larger sample sizes. Since microfluidics enables experiments with small volumes (including analysis of single cells or few cells), Raman is a leading microfluidic detection method. Specifically, Raman integration with microfluidic devices has strong applications in systems where lipid identification is necessary, common in biofuel research. For example, a lipid fluorescent assay is not selective enough and thus cannot identify molecular differences the way Raman can through molecular vibrations.
Sources: en.wikipedia.org
A diet that is heavy on grains, fish, and vegetables and light on meat, eggs, and dairy products. Low-stress lifestyles, which are proven significantly less stressful than that of the mainland inhabitants of Japan. A caring community, where older adults are not isolated and are taken better care of. High levels of activity, where locals work until an older age than the average age in other countries, and more emphasis on activities like walking and gardening to keep active. Spirituality, where a sense of purpose comes from involvement in spiritual matters and prayer eases the mind of stress and problems. Although these factors vary from those mentioned in the previous study, the culture of Okinawa has proven these factors to be important in its large population of centenarians.
Breast hypertrophy is a rare medical condition of the breast connective tissues in which the breasts become excessively large. The condition is often divided based on the severity into two types, macromastia and gigantomastia. Hypertrophy of the breast tissues may be caused by increased histologic sensitivity to certain hormones such as female sex hormones, prolactin, and growth factors. Breast hypertrophy is a benign progressive enlargement, which can occur in both breasts (bilateral) or only in one breast (unilateral). It was first scientifically described in 1648.
=== International growth: 2010s === The market for electronic cigarettes rose rapidly during the early 2010s and it started gaining attention in mainstream media. International tobacco companies dismissed e-cigarettes as a fad at first, but, recognizing a potential new market sector that could make smoking obsolete, they began to produce and market their own brands of e-cigarettes and acquire existing e-cigarette companies. Tobacco companies bought established e-cigarette companies. Blu eCigs, a prominent US e-cigarette manufacturer, was acquired by Lorillard Inc. for $135 million in April 2012. Japan Tobacco invested in Ploom. British American Tobacco was the first tobacco business to sell e-cigarettes in the UK and launched the e-cigarette Vype in July 2013. Imperial Tobacco's Fontem Ventures acquired the intellectual property owned by Hon Lik through Dragonite International Limited for $US 75 million in 2013 and launched Puritane in partnership with Boots UK. On 1 October 2013 Lorillard Inc. acquired another e-cigarette company, this time the UK based company SKYCIG. SKY was rebranded as blu.
Advanced delivery systems such as gene therapies, nanoparticles, or implants have been costly, and therefore, only patients within wealthy countries can afford them. This indicates that healthcare no longer considers equality and fairness. Another ethical concern is the issue of privacy. Digital tools have been used to determine and track patient medical adherence. Although these tools may help improve patient welfare, they may also be used to expose patient data, and there are increasing insecurities regarding patients' personal information.
Joshua Coon is a professor of chemistry and biomolecular chemistry and the inaugural holder of the Thomas and Margaret Pyle Chair at the University of Wisconsin–Madison, and an affiliate of the Morgridge Institute for Research. Coon develops scientific instruments to measure molecules in living systems. He focuses specifically on the use of mass spectrometry to measure the molecular mass of biomolecules, and its application to proteomics. Joshua Coon, along with John Syka, developed electron-transfer dissociation (ETD) while working as a postdoctoral student in Donald Hunt's lab at the University of Virginia.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.